References

Effect of Rituximab on the Peripheral Blood and Cerebrospinal Fluid B Cells in Patients with Primary Progressive Multiple Sclerosis

10.1001/archneur.62.2.258 · ExternalCitation · doi-reference

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

10.1001/jamaneurol.2023.1184 · ExternalCitation · doi-reference

Rituximab in Patients with Primary Progressive Multiple Sclerosis: Results of a Randomized Double-blind Placebo-controlled Multicenter Trial

10.1002/ana.21867 · ExternalCitation · doi-reference

Gut Microbiome in Progressive Multiple Sclerosis

10.1002/ana.26084 · ExternalCitation · doi-reference

A Genetic Risk Variant for Multiple Sclerosis Severity Is Associated with Brain Atrophy

10.1002/ana.26807 · ExternalCitation · doi-reference

Fecal Microbiota Transplantation for Rheumatoid Arthritis: A Case Report

10.1002/ccr3.3677 · ExternalCitation · doi-reference

Anti-CD20 Therapies for Multiple Sclerosis: Current Status and Future Perspectives

10.1007/s00415-021-10744-x · ExternalCitation · doi-reference

A Novel Probiotic Strain Exerts Therapeutic Effects on Mouse Model of Multiple Sclerosis by Altering the Expression of Inflammasome and IDO Genes and Modulation of T Helper Cytokine Profile

10.1007/s11011-021-00857-7 · ExternalCitation · doi-reference

CARs: A New Approach for the Treatment of Autoimmune Diseases

10.1007/s11427-022-2212-5 · ExternalCitation · doi-reference

Diet, Gut Microbiota, and Vitamins D + A in Multiple Sclerosis

10.1007/s13311-017-0581-4 · ExternalCitation · doi-reference

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

10.1007/s40120-023-00518-0 · ExternalCitation · doi-reference

Ublituximab: First Approval

10.1007/s40265-023-01854-z · ExternalCitation · doi-reference

Treatment of Multiple Sclerosis: A Review

10.1016/j.amjmed.2020.05.049 · ExternalCitation · doi-reference

Bifidobacterium Animalis in Combination with Human Origin of Lactobacillus Plantarum Ameliorate Neuroinflammation in Experimental Model of Multiple Sclerosis by Altering CD4+ T Cell Subset Balance

10.1016/j.biopha.2017.08.117 · ExternalCitation · doi-reference

Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism

10.1016/j.cell.2020.02.035 · ExternalCitation · doi-reference

Gut Microbiome of Multiple Sclerosis Patients and Paired Household Healthy Controls Reveal Associations with Disease Risk and Course

10.1016/j.cell.2022.08.021 · ExternalCitation · doi-reference

Outer Membrane Vesicles of a Human Commensal Mediate Immune Regulation and Disease Protection

10.1016/j.chom.2012.08.004 · ExternalCitation · doi-reference

Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila

10.1016/j.chom.2019.10.008 · ExternalCitation · doi-reference

Amelioration of Experimental Autoimmune Encephalomyelitis by Probiotic Mixture Is Mediated by a Shift in T Helper Cell Immune Response

10.1016/j.clim.2013.01.001 · ExternalCitation · doi-reference

Pleiotropic Roles of Bile Acids in Metabolism

10.1016/j.cmet.2013.03.013 · ExternalCitation · doi-reference

Home-Based Exercise Training Influences Gut Bacterial Levels in Multiple Sclerosis

10.1016/j.ctcp.2021.101463 · ExternalCitation · doi-reference

The Molecular Basis of Nutritional Intervention in Multiple Sclerosis: A Narrative Review

10.1016/j.ctim.2011.06.006 · ExternalCitation · doi-reference

Long-Term Exposure to Air Pollution and the Incidence of Multiple Sclerosis: A Population-Based Cohort Study

10.1016/j.envres.2018.06.003 · ExternalCitation · doi-reference

Cognate Interaction-Dependent Pathogenicity of Meningeal B Cells Drives Neuroinflammation Relapse

10.1016/j.immuni.2025.06.016 · ExternalCitation · doi-reference

Fecal Microbiota Transplantation: Emerging Applications in Autoimmune Diseases

10.1016/j.jaut.2023.103038 · ExternalCitation · doi-reference

Fecal Microbiota Transplantation in the Treatment of Systemic Lupus Erythematosus: What We Learnt from the Explorative Clinical Trial

10.1016/j.jaut.2023.103058 · ExternalCitation · doi-reference

Gut Microbiota and Obesity: Impact of Antibiotics and Prebiotics and Potential for Musculoskeletal Health

10.1016/j.jshs.2019.04.004 · ExternalCitation · doi-reference

Increased Intestinal Permeability in Primary Sjögren’s Syndrome and Multiple Sclerosis

10.1016/j.jtauto.2021.100082 · ExternalCitation · doi-reference

CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Two Patients with Multiple Sclerosis

10.1016/j.medj.2024.03.002 · ExternalCitation · doi-reference

Bile Acid Metabolites Predict Multiple Sclerosis Progression and Supplementation Is Safe in Progressive Disease

10.1016/j.medj.2024.09.011 · ExternalCitation · doi-reference

Acquired Hemophilia A and Other Autoimmune Diseases after Alemtuzumab Therapy for Multiple Sclerosis: A Report of Two Cases

10.1016/j.msard.2020.102181 · ExternalCitation · doi-reference

Lifetime Physical Activity Is Associated with Gut Bacteria and Brain Health in People with Multiple Sclerosis: Focus on Physical Activity Intensity

10.1016/j.msard.2022.103639 · ExternalCitation · doi-reference

CAR T Cells for Multiple Sclerosis: Engineering T Cells to Disrupt Chronic B Cell–Driven Neuroinflammation

10.1016/j.msard.2025.106812 · ExternalCitation · doi-reference

Microbial Regulation of Host Physiology by Short-Chain Fatty Acids

10.1016/j.tim.2021.02.001 · ExternalCitation · doi-reference

Microbiota-Produced Immune Regulatory Bile Acid Metabolites Control Central Nervous System Autoimmunity

10.1016/j.xcrm.2025.102028 · ExternalCitation · doi-reference

Gut Microbiota and Metabolites Are Linked to Disease Progression in Multiple Sclerosis

10.1016/j.xcrm.2025.102055 · ExternalCitation · doi-reference

Redefining Multiple Sclerosis with CAR-T Cell Therapy

10.1016/j.ymthe.2025.12.022 · ExternalCitation · doi-reference

Alemtuzumab versus Interferon Beta 1a as First-Line Treatment for Patients with Relapsing-Remitting Multiple Sclerosis: A Randomised Controlled Phase 3 Trial

10.1016/s0140-6736(12)61769-3 · ExternalCitation · doi-reference

A Comprehensive Repertoire of Prokaryotic Species Identified in Human Beings

10.1016/s1473-3099(15)00293-5 · ExternalCitation · doi-reference

Epstein-Barr Virus as a Cause of Multiple Sclerosis: Opportunities for Prevention and Therapy

10.1016/s1474-4422(22)00471-9 · ExternalCitation · doi-reference

B Cell-Targeting Chimeric Antigen Receptor T Cells as an Emerging Therapy in Neuroimmunological Diseases

10.1016/s1474-4422(24)00140-6 · ExternalCitation · doi-reference

The Intestinal Barrier in Disorders of the Central Nervous System

10.1016/s2468-1253(22)00241-2 · ExternalCitation · doi-reference

Local Immune Effector Cell-Associated Toxicity Syndrome in CAR T-Cell Treated Patients with Autoimmune Disease: An Observational Study

10.1016/s2665-9913(25)00091-8 · ExternalCitation · doi-reference

Phylogenetic Distribution of Three Pathways for Propionate Production within the Human Gut Microbiota

10.1038/ismej.2014.14 · ExternalCitation · doi-reference

Diversity, Stability and Resilience of the Human Gut Microbiota

10.1038/nature11550 · ExternalCitation · doi-reference

Treg Induction by a Rationally Selected Mixture of Clostridia Strains from the Human Microbiota

10.1038/nature12331 · ExternalCitation · doi-reference

Alterations of the Human Gut Microbiome in Multiple Sclerosis

10.1038/ncomms12015 · ExternalCitation · doi-reference

Host Microbiota Constantly Control Maturation and Function of Microglia in the CNS

10.1038/nn.4030 · ExternalCitation · doi-reference

The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic

10.1038/nrgastro.2014.66 · ExternalCitation · doi-reference

The Effects of Different Dietary Fiber Pectin Structures on the Gastrointestinal Immune Barrier: Impact via Gut Microbiota and Direct Effects on Immune Cells

10.1038/s12276-020-0449-2 · ExternalCitation · doi-reference

Microbiota in Health and Diseases

10.1038/s41392-022-00974-4 · ExternalCitation · doi-reference

Multiple Sclerosis: Molecular Pathogenesis and Therapeutic Intervention

10.1038/s41392-025-02415-4 · ExternalCitation · doi-reference

Scarless Circular mRNA-Based CAR-T Cell Therapy Elicits Superior Antitumor Efficacy

10.1038/s41392-025-02512-4 · ExternalCitation · doi-reference

CAR-T Cell Therapy-Related Cytokine Release Syndrome and Therapeutic Response Is Modulated by the Gut Microbiome in Hematologic Malignancies

10.1038/s41467-022-32960-3 · ExternalCitation · doi-reference

Elevated Genetic Risk for Multiple Sclerosis Emerged in Steppe Pastoralist Populations

10.1038/s41586-023-06618-z · ExternalCitation · doi-reference

Gut Microbiome Correlates of Response and Toxicity Following Anti-CD19 CAR T Cell Therapy

10.1038/s41591-022-01702-9 · ExternalCitation · doi-reference

A Non-Antibiotic-Disrupted Gut Microbiome Is Associated with Clinical Responses to CD19-CAR-T Cell Cancer Immunotherapy

10.1038/s41591-023-02234-6 · ExternalCitation · doi-reference

Broad Rim Lesions Are a New Pathological and Imaging Biomarker for Rapid Disease Progression in Multiple Sclerosis

10.1038/s41591-025-03625-7 · ExternalCitation · doi-reference

Noncanonical and Mortality-Defining Toxicities of CAR T Cell Therapy

10.1038/s41591-025-03813-5 · ExternalCitation · doi-reference

Modulation of Serotonin Signaling/Metabolism by Akkermansia muciniphila and Its Extracellular Vesicles through the Gut-Brain Axis in Mice

10.1038/s41598-020-79171-8 · ExternalCitation · doi-reference

Multiple Sclerosis Patients Have a Distinct Gut Microbiota Compared to Healthy Controls

10.1038/srep28484 · ExternalCitation · doi-reference

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

10.1056/nejmc1704610 · ExternalCitation · doi-reference

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

10.1056/nejmoa044397 · ExternalCitation · doi-reference

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

10.1056/nejmoa051782 · ExternalCitation · doi-reference

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

10.1056/nejmoa0706383 · ExternalCitation · doi-reference

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

10.1056/nejmoa1601277 · ExternalCitation · doi-reference

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

10.1056/nejmoa1606468 · ExternalCitation · doi-reference

Ofatumumab versus Teriflunomide in Multiple Sclerosis

10.1056/nejmoa1917246 · ExternalCitation · doi-reference

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

10.1056/nejmoa2201904 · ExternalCitation · doi-reference

CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-Up

10.1056/nejmoa2308917 · ExternalCitation · doi-reference

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

10.1056/nejmoa2309439 · ExternalCitation · doi-reference

Chimeric Antigen Receptor Therapy

10.1056/nejmra1706169 · ExternalCitation · doi-reference

Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor

10.1073/pnas.0509592103 · ExternalCitation · doi-reference

Obeticholic Acid, a Synthetic Bile Acid Agonist of the Farnesoid X Receptor, Attenuates Experimental Autoimmune Encephalomyelitis

10.1073/pnas.1524890113 · ExternalCitation · doi-reference

Multiple Sclerosis and Gut Microbiota: Lachnospiraceae from the Ileum of MS Twins Trigger MS-like Disease in Germfree Transgenic Mice—An Unbiased Functional Study

10.1073/pnas.2419689122 · ExternalCitation · doi-reference

The Immune-Enhancing Effects of Dietary Fibres and Prebiotics

10.1079/bjnbjn/2002541 · ExternalCitation · doi-reference

Effects of Long-Term Administration of Multi-Strain Probiotic on Circulating Levels of BDNF, NGF, IL-6 and Mental Health in Patients with Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial

10.1080/1028415x.2020.1758887 · ExternalCitation · doi-reference

Role of Environmental Factors in Multiple Sclerosis

10.1080/14737175.2021.1978843 · ExternalCitation · doi-reference

The Role of Fecal Microbiota Transplantation (FMT) in Treating Patients with Multiple Sclerosis

10.1080/14737175.2023.2250919 · ExternalCitation · doi-reference

Risk of Opportunistic Infections in Patients Treated with Alemtuzumab for Multiple Sclerosis

10.1080/14740338.2018.1483330 · ExternalCitation · doi-reference

Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators

10.1097/jim.0000000000000192 · ExternalCitation · doi-reference

Clinical Adverse Effects of Natalizumab

10.1097/md.0000000000011507 · ExternalCitation · doi-reference

Therapeutic Faecal Microbiota Transplantation

10.1097/mog.0000000000000027 · ExternalCitation · doi-reference

Large-Scale Validation of Single Nucleotide Polymorphisms in Gene Regions

10.1101/gr.2421604 · ExternalCitation · doi-reference

Formation of Propionate and Butyrate by the Human Colonic Microbiota

10.1111/1462-2920.13589 · ExternalCitation · doi-reference

Modulation of Multiple Sclerosis Risk and Pathogenesis by the Gut Microbiota: Complex Interactions between Host Genetics, Bacterial Metabolism, and Diet

10.1111/imr.13343 · ExternalCitation · doi-reference

Prebiotics Enhance Survival and Prolong the Retention Period of Specific Probiotic Inocula in an in Vivo Murine Model

10.1111/j.1365-2672.2007.03469.x · ExternalCitation · doi-reference

Pharmacological Properties, Toxicology and Scientific Rationale for the Use of Natalizumab (Tysabri®) in Inflammatory Diseases

10.1111/j.1527-3458.2007.00003.x · ExternalCitation · doi-reference

High Frequency of Intestinal T H 17 Cells Correlates with Microbiota Alterations and Disease Activity in Multiple Sclerosis

10.1126/sciadv.1700492 · ExternalCitation · doi-reference

Interactions Between the Microbiota and the Immune System

10.1126/science.1223490 · ExternalCitation · doi-reference

Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer

10.1126/science.aaa4967 · ExternalCitation · doi-reference

In Vivo CAR T Cell Generation to Treat Cancer and Autoimmune Disease

10.1126/science.ads8473 · ExternalCitation · doi-reference

Treatment of a Patient with Severe Systemic Sclerosis (SSc) Using CD19-Targeted CAR T Cells

10.1136/ard-2023-223952 · ExternalCitation · doi-reference

CD19-CAR T-Cell Therapy Induces Deep Tissue Depletion of B Cells

10.1136/ard-2024-226142 · ExternalCitation · doi-reference

What Defines a Healthy Gut Microbiome?

10.1136/gutjnl-2024-333378 · ExternalCitation · doi-reference

Alemtuzumab Treatment of Multiple Sclerosis: Long-Term Safety and Efficacy

10.1136/jnnp-2014-307721 · ExternalCitation · doi-reference

Microbial Metabolites and Gut Immunology

10.1146/annurev-immunol-090222-102035 · ExternalCitation · doi-reference

Protection of Fecal Microbiota Transplantation in a Mouse Model of Multiple Sclerosis

10.1155/2020/2058272 · ExternalCitation · doi-reference

Fecal Microbiota Transplants for Inflammatory Bowel Disease Treatment: Synthetic- and Engineered Communities-Based Microbiota Transplants Are the Future

10.1155/2022/9999925 · ExternalCitation · doi-reference

Bile Acid Metabolism Is Altered in Multiple Sclerosis and Supplementation Ameliorates Neuroinflammation

10.1172/jci129401 · ExternalCitation · doi-reference

Targeting the Gut to Treat Multiple Sclerosis

10.1172/jci143774 · ExternalCitation · doi-reference

Altered Intestinal Permeability in Patients with Relapsing–Remitting Multiple Sclerosis: A Pilot Study

10.1177/1352458516652498 · ExternalCitation · doi-reference

A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis

10.1177/1352458520918375 · ExternalCitation · doi-reference

Rapid and Sustained B-Cell Depletion with Subcutaneous Ofatumumab in Relapsing Multiple Sclerosis: APLIOS, a Randomized Phase-2 Study

10.1177/13524585211044479 · ExternalCitation · doi-reference

Effect of Ofatumumab versus Placebo in Relapsing Multiple Sclerosis Patients from Japan and Russia: Phase 2 APOLITOS Study

10.1177/13524585211055934 · ExternalCitation · doi-reference

‘Anti-B Cell CAR-T Therapy in Multiple Sclerosis Is Simply a More Profound Immunoablation’: Yes

10.1177/13524585251364140 · ExternalCitation · doi-reference

Anti-B-Cell CAR-T Therapy in Multiple Sclerosis Is Simply a More Profound Immunoablation? No

10.1177/13524585251364144 · ExternalCitation · doi-reference

Alemtuzumab in the Treatment of Multiple Sclerosis: Key Clinical Trial Results and Considerations for Use

10.1177/1756285614563522 · ExternalCitation · doi-reference

The Potential Role for Ocrelizumab in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects

10.1177/1756285615601933 · ExternalCitation · doi-reference

Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data from the Real World

10.1177/1756285617722706 · ExternalCitation · doi-reference

Nutrition Facts in Multiple Sclerosis

10.1177/1759091414568185 · ExternalCitation · doi-reference

CAR T Cells in Autoimmunity: Game Changer or Stepping Stone?

10.1182/blood.2024025413 · ExternalCitation · doi-reference

Late Complications and Long-Term Care of Adult CAR T-Cell Patients

10.1182/hematology.2024000534 · ExternalCitation · doi-reference

10.1186/s12916-025-04041-x

10.1186/s12916-025-04041-x · ExternalCitation · doi-reference

Beneficial Effects on Host Energy Metabolism of Short-Chain Fatty Acids and Vitamins Produced by Commensal and Probiotic Bacteria

10.1186/s12934-017-0691-z · ExternalCitation · doi-reference

N-Acetylglucosamine Inhibits Inflammation and Neurodegeneration Markers in Multiple Sclerosis: A Mechanistic Trial

10.1186/s12974-023-02893-9 · ExternalCitation · doi-reference

CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity

10.1212/nxi.0000000000200080 · ExternalCitation · doi-reference

Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients with Multiple Sclerosis

10.1212/nxi.0000000000200355 · ExternalCitation · doi-reference

Alemtuzumab CARE-MS II 5-Year Follow-Up

10.1212/wnl.0000000000004354 · ExternalCitation · doi-reference

Vitiligo after Alemtuzumab Treatment

10.1212/wnl.0000000000006648 · ExternalCitation · doi-reference

Defining the Clinical Course of Multiple Sclerosis

10.1212/wnl.46.4.907 · ExternalCitation · doi-reference

10.1371/journal.pone.0065911

10.1371/journal.pone.0065911 · ExternalCitation · doi-reference

10.1371/journal.pone.0100883

10.1371/journal.pone.0100883 · ExternalCitation · doi-reference

10.1371/journal.pone.0137429

10.1371/journal.pone.0137429 · ExternalCitation · doi-reference

10.20944/preprints202501.1215.v1

10.20944/preprints202501.1215.v1 · ExternalCitation · doi-reference

Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis

10.2174/1570159x19666210217084827 · ExternalCitation · doi-reference

10.3389/fimmu.2017.01751

10.3389/fimmu.2017.01751 · ExternalCitation · doi-reference

10.3389/fimmu.2019.00385

10.3389/fimmu.2019.00385 · ExternalCitation · doi-reference

10.3389/fimmu.2021.661493

10.3389/fimmu.2021.661493 · ExternalCitation · doi-reference

10.3389/fimmu.2021.707734

10.3389/fimmu.2021.707734 · ExternalCitation · doi-reference

10.3389/fimmu.2022.956907

10.3389/fimmu.2022.956907 · ExternalCitation · doi-reference

10.3389/fimmu.2025.1515730

10.3389/fimmu.2025.1515730 · ExternalCitation · doi-reference

10.3389/fimmu.2025.1703146

10.3389/fimmu.2025.1703146 · ExternalCitation · doi-reference

10.3389/fimmu.2026.1769792

10.3389/fimmu.2026.1769792 · ExternalCitation · doi-reference

10.3389/fmed.2025.1607899

10.3389/fmed.2025.1607899 · ExternalCitation · doi-reference

10.3389/fneur.2020.00996

10.3389/fneur.2020.00996 · ExternalCitation · doi-reference

10.3389/fneur.2022.824926

10.3389/fneur.2022.824926 · ExternalCitation · doi-reference

10.3389/fnins.2023.1241418

10.3389/fnins.2023.1241418 · ExternalCitation · doi-reference

10.3389/fnut.2022.773298

10.3389/fnut.2022.773298 · ExternalCitation · doi-reference

10.3390/biomedicines14020296

10.3390/biomedicines14020296 · ExternalCitation · doi-reference

10.3390/biomedicines7010020

10.3390/biomedicines7010020 · ExternalCitation · doi-reference

10.3390/cells13060497

10.3390/cells13060497 · ExternalCitation · doi-reference

10.3390/cells15010023

10.3390/cells15010023 · ExternalCitation · doi-reference

10.3390/ijerph13040379

10.3390/ijerph13040379 · ExternalCitation · doi-reference

10.3390/ijms231911846

10.3390/ijms231911846 · ExternalCitation · doi-reference

10.3390/ijms241914925

10.3390/ijms241914925 · ExternalCitation · doi-reference

10.3390/ijms25063198

10.3390/ijms25063198 · ExternalCitation · doi-reference

10.3390/ijms25094834

10.3390/ijms25094834 · ExternalCitation · doi-reference

10.3390/microorganisms12071476

10.3390/microorganisms12071476 · ExternalCitation · doi-reference

10.3390/microorganisms13122803

10.3390/microorganisms13122803 · ExternalCitation · doi-reference

10.3390/molecules28186438

10.3390/molecules28186438 · ExternalCitation · doi-reference

10.3390/nu10091175

10.3390/nu10091175 · ExternalCitation · doi-reference

The Impact of Diet and Lifestyle on Gut Microbiota and Human Health

10.3390/nu7010017 · ExternalCitation · doi-reference

10.3390/nu9091021

10.3390/nu9091021 · ExternalCitation · doi-reference

Health Effects of Probiotics and Prebiotics A Literature Review on Human Studies

10.3402/fnr.v45i0.1790 · ExternalCitation · doi-reference

Prevention and Therapy of JC Polyomavirus-Mediated Progressive Multifocal Leukoencephalopathy—A Realistic Possibility?

10.4414/smw.2017.14520 · ExternalCitation · doi-reference